Liu L N, Cui Y S, Liu Y Z, Wang Y M, Xiang P, Liang L J, Li Y R, Fang B J
Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China.
Zhonghua Xue Ye Xue Za Zhi. 2024 Aug 14;45(8):772-775. doi: 10.3760/cma.j.cn121090-20231031-00241.
To determine the efficacy and safety of selinexor combined with venetoclax (VEN) and azactitidine (AZA) for patients with relapsed and/or refractory acute myeloid leukemia (R/R AML) . Twelve patients with R/R AML treated with selinexor plus VEN and AZA in the Affiliated Cancer Hospital of Zhengzhou University from May 2022 to May 2023 were included. Their clinical data were retrospectively analyzed. Among the 12 R/R AML patients, 5 (41.7%) achieved complete remission (CR) , 1 (8.3%) achieved CR with incomplete hematological recovery, and 5 (41.7%) achieved partial remission. The median time to reach CR was 28 (16-59) days. The median PFS was 61 (15-300) days. The main adverse event of the regimen was hematological toxicity. No chemotherapy-related deaths were observed. The combination of selinexor plus VEN and AZA is an effective treatment for R/R AML patients.
确定塞利尼索联合维奈克拉（VEN）和阿扎胞苷（AZA）治疗复发和/或难治性急性髓系白血病（R/R AML）患者的疗效和安全性。纳入了2022年5月至2023年5月在郑州大学附属肿瘤医院接受塞利尼索联合VEN和AZA治疗的12例R/R AML患者。对他们的临床资料进行回顾性分析。在这12例R/R AML患者中，5例（41.7%）达到完全缓解（CR），1例（8.3%）达到血液学未完全恢复的CR，5例（41.7%）达到部分缓解。达到CR的中位时间为28（16 - 59）天。中位无进展生存期为61（15 - 300）天。该方案的主要不良事件为血液学毒性。未观察到化疗相关死亡。塞利尼索联合VEN和AZA是治疗R/R AML患者的有效方法。
